Clinical Trial

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2021-04-27; most recent amendment 2026-02-17.
Status change: Recruiting → Active, Not Recruiting 2026-02-17
Trial Details
NCT Number NCT04868877
Lead Sponsor Merus B.V.
Conditions Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Enrollment 194 participants
Start Date 2021-04-28
Primary Completion 2026-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-02-19